Oxford BioTherapeutics

Profound Bio

This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.

Ona Therapeutics

This company develops antibody-drug conjugates to treat patients with advanced and metastatic cancers which have become resistant to existing therapies.

Nectin Therapeutics

This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.

TORL

TORL BioTherapeutics develops antibody-based immunotherapies and drug conjugates to treat patients with various solid tumours and haematological cancers.

Adaptam Therapeutics

Adaptam Therapeutics develops antibody-based therapies for solid tumours to treat oncology patients by targeting immunosuppressive myeloid cells.

Emergence Therapeutics

This biopharmaceutical company develops antibody-drug conjugate immunotherapies to treat solid tumours for patients with high unmet medical needs.

Promatix

Promatix develops antibody-drug conjugates for cancer treatment using a proprietary multi-omics platform to identify and target specific tumour markers.

TORL BioTherapeutics

This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.